uniQure NV :QURE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Tue, 07 Nov 2017 13:07:39 +0000 Categories: Yahoo FinanceGet free summary analysis uniQure NV reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of uniQure NV – Amgen Inc., bluebird bio, Inc. and BioMarin Pharmaceutical Inc. (AMGN-US, BLUE-US and BMRN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more
(Read more...)
UniQure reports 3Q loss Wed, 01 Nov 2017 11:17:30 +0000 On a per-share basis, the Amsterdam-based company said it had a loss of 40 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
uniQure Announces Pricing of its Public Offering Wed, 25 Oct 2017 00:14:48 +0000 LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 24, 2017-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia ...
uniQure Announces Proposed Public Offering Mon, 23 Oct 2017 20:06:28 +0000 LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 23, 2017-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia ...
Why uniQure N.V. Stock Is Hopping Today Fri, 20 Oct 2017 19:00:00 +0000 Investors are cheering the FDA's surprisingly progressive take on uniQure's novel hemophilia B gene therapy candidate.
Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3 Thu, 19 Oct 2017 19:28:30 +0000 Uniqure NV (NASDAQ:QURE) investors are overwhelmingly excited today after the drug maker announced advancement of AMT-061, a Padua variant FIX AAV5 gene therapy, in hemophilia B, into a pivotal phase 3 trial in 3Q18. Cowen analyst Ritu Baral commented, "Surprisingly to us, this payload change (Padua FIX variant has a 2 nucleotide change leading to a single amino acid substitution) will be allowed to start clinical trials under the same IND and maintain FDA Breakthrough Designation and EMA PRIME Designation granted to AMT-060. "We do note other than the 2 nucleotide substitution, AMT-060 and AMT-061 are otherwise structurally identical, which we find encouraging given the predictability and duration of response seen with AMT-060 as well as excellent safety and low population seropositivity to date.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.59 (median winner: 1.53)
GSA Rank: 70.54 (winner: 75.66)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.